Intrahepatic Cholangiocarcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This multicentre, phase 1/2, open-label study enrolled adult patients with unresectable iCCA with FGFR2 fusion, who progressed, were intolerant or not eligible to first-line chemotherapy (NCT01752920).
|
30420614 |
2019 |
Intrahepatic Cholangiocarcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We demonstrate that the irreversible FGFR inhibitor TAS-120 provides clinical benefit in patients with resistance to BGJ398 or Debio 1347 and overcomes several FGFR2 mutations in ICC models.<i>This article is highlighted in the In This Issue feature, p. 983</i>.
|
31109923 |
2019 |
Intrahepatic Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conclusion: Our data provide a proof of principle that upfront treatment with the BGJ398 + ganetespib combo improves therapeutic targeting of FGFR2 fusions in an experimental setting, which may be relevant to precision medicine approaches to FF-driven ICC.
|
30067876 |
2019 |
Intrahepatic Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genomic studies have shown that FGFR2 aberrations are implicated in approximately 15% of intrahepatic cholangiocarcinomas, which make FGFR2 aberrations (Achilles heel) as potential novel targets in the management of cholangiocarcinoma.
|
31255945 |
2019 |
Intrahepatic Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using break-apart probes and by determining the ratios of FGFR2/chromosome enumeration probe (CEP) 10 double-color probes, we evaluated 122 ICCs for the presence of FGFR2 translocations and amplifications, respectively, by fluorescence in situ hybridization.
|
29514108 |
2018 |
Intrahepatic Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor 2 (FGFR2) was demonstrated to correlate to the progression and prognosis of intrahepatic cholangiocarcinoma (ICC) by numerous evidences.
|
30160357 |
2018 |
Intrahepatic Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor 2 ( FGFR2) fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas.
|
29182496 |
2018 |
Intrahepatic Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, polyclonal secondary <i>FGFR2</i> mutations represent an important clinical resistance mechanism that may guide the development of future therapeutic strategies.<b>Significance:</b> We report the first genetic mechanisms of clinical acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive ICC.
|
28034880 |
2017 |
Intrahepatic Cholangiocarcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analyses of genetic alterations have identified those that might be targeted therapeutically, such as fusions in the FGFR2 gene and mutations in genes encoding isocitrate dehydrogenases (in approximately 60% of iCCAs) or amplifications at 11q13 and 6p21 (in approximately 15% of HCCs).
|
28043904 |
2017 |
Intrahepatic Cholangiocarcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Specificities are observed for some alterations and anatomical subtypes: frequent fibroblast growth factor receptor 2 (FGFR2) and isocitrate dehydrogenase 1/2 (IDH1/2) alterations are specific to intrahepatic cholangiocarcinomas (ICCs), whereas frequent ERBB2 oncogene alterations are specific to extrahepatic cholangiocarcinomas (ECCs) and gallbladder carcinomas (GBCs).
|
28628842 |
2017 |
Intrahepatic Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In 18 evaluable patients with FGFR genetic alterations, 3 confirmed partial responses (two intrahepatic cholangiocarcinomas (iCCA) with FGFR2 fusions and one urothelial cancer with FGFR2 and FGF19 amplification) and two durable stable disease at ⩾16 weeks with tumour reduction (FGFR2 fusion-positive iCCA and adrenocortical carcinoma with FGFR1 amplification) were observed.
|
28972963 |
2017 |
Intrahepatic Cholangiocarcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recent genomic analysis of cholangiocarcinoma has revealed the presence of fibroblast growth factor receptor 2 (FGFR2) fusion proteins in up to 13% of intrahepatic cholangiocarcinoma (iCCA).
|
27216979 |
2016 |
Intrahepatic Cholangiocarcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic analyses revealed that KRAS mutation was significantly more frequent in type 1 ICC, whereas IDH mutation and FGFR2 translocation were restricted to type 2 ICC.
|
27259014 |
2016 |
Intrahepatic Cholangiocarcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Screening of a cohort of 107 iCCA patients reveals that FGFR2 fusions represent the most recurrent targetable alteration (45%, 17/107), while they are rarely present in other primary liver tumours (0/100 of hepatocellular carcinoma (HCC); 1/21 of mixed iCCA-HCC).
|
25608663 |
2015 |
Intrahepatic Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Genomic spectra of biliary tract cancer.
|
26258846 |
2015 |
Intrahepatic Cholangiocarcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
|
24837095 |
2014 |
Intrahepatic Cholangiocarcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Four (14%) of the ICC cases featured novel gene fusions involving the tyrosine kinases FGFR2 and NTRK1 (FGFR2-KIAA1598, FGFR2-BICC1, FGFR2-TACC3, and RABGAP1L-NTRK1).
|
24563076 |
2014 |
Intrahepatic Cholangiocarcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
FGFR2 fusions and ERRFI mutations may represent novel targets in sporadic intrahepatic cholangiocarcinoma and trials should be characterized in larger cohorts of patients with these aberrations.
|
24550739 |
2014 |